Eton Pharmaceuticals ( (ETON) ) has released its Q1 earnings. Here is a breakdown of the information Eton Pharmaceuticals presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, with a portfolio of seven commercial products and six additional candidates in late-stage development.
In the first quarter of 2025, Eton Pharmaceuticals reported significant financial growth, with revenues reaching $17.3 million, marking a 117% increase from the previous year. The company also relaunched two key products, INCRELEX® and GALZIN®, and made strategic advancements in its development pipeline.
Key financial highlights include a 76% growth in product sales, driven by ALKINDI SPRINKLE® and the addition of INCRELEX®. The company reported a non-GAAP net income of $2.4 million and an adjusted EBITDA of $3.7 million. Eton also announced the submission of a New Drug Application for ET-600 and the anticipated launch of ET-400.
Eton’s strategic initiatives included out-licensing INCRELEX® rights outside the U.S. and expanding its Wilson disease franchise with the acquisition of GALZIN® and the introduction of ET-700. The company expects continued growth in product sales and aims to exit 2025 with an $80 million annual revenue run rate.
Looking forward, Eton Pharmaceuticals is poised for a promising year with multiple product launches and ongoing development of late-stage candidates, reinforcing its position as a leader in the ultra-rare disease sector.